Home > Business > Guest Reports

Huons BioPharma’s Hutox formulation set for smooth distribution in China

Published: 17 Mar. 2026, 09:58

Huons BioPharma delivers the first shipment of its botulinum toxin product, ‘Hutox,’ to the Chinese market. [HUONS BIOPHARMA]

Huons BioPharma, a subsidiary of Huons Global, sent out the first shipment of its botulinum toxin product, “Hutox,” to China as the firm sets its sights on the neighboring market.

Kim Yeong-mok, Huons BioPharma’s CEO, announced on Monday that the company has signed a contract with a Chinese cooperative company, IMeik Technology, on logistics for the supply.

Hutox is a formulation for both cosmetic and medical purposes and consists mainly of botulinum toxin type A produced by Clostridium botulinum type A.

IMeik Technology has held exclusive export and logistic rights for Huons BioPharma’s botulinum toxin in the Chinese market since 2022. In January, the National Medical Products Administration of China issued 100-unit formulation approval to Hutox after sequential phase development.

The drug is expected to enter the market late this year after going through quality examinations in China. This makes Hutox the seventh product to be industrialized in the Chinese market and makes Huons BioPharma the second Korean company to sell botulinum toxin in the market.

“From this first shipment, our company will maintain close association with IMeik Technology for better logistics and marketing in the Chinese market,” a Huons BioPharma representative said. “Hutox is highly expected to post a global sales record starting this year.”

BY LEE DAHYUN [[email protected]]

What is “Promoted Content”?

“Promoted Content” articles are written by our staff reporters. They are promoted to some extent by an external company.

Promoted Content is not the same as “Guest Reports,” which are paid advertorials.
Our reporters and editors retain complete editorial independence in the conception and production of Promoted Content.